A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of AMPYRA on a number of symptoms in
Parkinson's disease. AMPYRA is a medication approved by FDA for gait dysfunction in multiple
sclerosis. There are multiple studies to suggest that persons with multiple sclerosis benefit
from this medication and have major improvements in gait after taking this medication.
However, this medication was never studied in Parkinson's disease. This study aims to learn
about possible benefits of AMPYRA in Parkinson's disease (PD).